- Home
- GIGM vs BCTX Comparison
GIGM vs BCTX Comparison
Compare GIGM & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | BCTX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | Taiwan | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 17.0M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | BCTX |
|---|---|---|
| Price | $1.46 | $9.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 4.0K | ★ 52.6K |
| Earning Date | 10-30-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $6.00 |
| 52 Week High | $1.89 | $98.20 |
Technical Indicators
Market Signals| Indicator | GIGM | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 48.32 |
| Support Level | $1.50 | $8.55 |
| Resistance Level | $1.56 | $9.36 |
| Average True Range (ATR) | 0.05 | 1.03 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 13.33 | 25.99 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.